Investigation of miR-21, miR-150, miR-155 Expression Levels in Chronic Myeloid Leukemia Patients

Purpose: In this study, the relationship between CML and the expression levels of miR-21, miR-150, and miR-155, which could be used in the follow-up of CML patients, was investigated. Materials and Methods: RNA and miRNA were extracted from peripheral blood samples of patient and control samples....

Full description

Saved in:
Bibliographic Details
Main Authors: Hüseyin Avcılar, Hatice Altın, Sevil Şimşek, Leylagül Kaynar
Format: Article
Language:English
Published: Kirsehir Ahi Evran University 2025-04-01
Series:Ahi Evran Medical Journal
Subjects:
Online Access:https://dergipark.org.tr/tr/download/article-file/3263928
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850194809694715904
author Hüseyin Avcılar
Hatice Altın
Sevil Şimşek
Leylagül Kaynar
author_facet Hüseyin Avcılar
Hatice Altın
Sevil Şimşek
Leylagül Kaynar
author_sort Hüseyin Avcılar
collection DOAJ
description Purpose: In this study, the relationship between CML and the expression levels of miR-21, miR-150, and miR-155, which could be used in the follow-up of CML patients, was investigated. Materials and Methods: RNA and miRNA were extracted from peripheral blood samples of patient and control samples. Targe-ted miRNA expression levels from cDNA samples were analyzed by real-time PCR method. Results: miRNA expression level was determined as 1.0 in the control group. In the newly diagnosed group, the mean miR-21 fold change was 0.6, miR-150 fold change was 0.3, and miR-155 fold change was 0.5. fold changes for miR-21, miR-150 and miR-155 were found to be 1.4, 0.5 and 2.4 fold, respectively, in the imatinib treatment group. In the nilotinib treatment group, miR-21 level was 3.5, miR-150 level 0.5, and miR-155 level 4.3. In the dasatinib treatment group, fold change was 0.8 for miR-21, 2.1 for miR-150, and 0.5 for miR-155. The mean miR-21 level was found to be 3.2, miR-150 level 1.0 and miR-155 level 2.8. MiR-150 levels were found to be lower in the newly diagnosed group, imatinib group and nilotinib group than in the control samples. This difference between the new diagnosis group (p=0.07484) and the nilotinib group (p=0.01541) is statistically signi-ficant. No significant difference was found between patients and controls in terms of miR-21 and miR-155 levels. Conclusion: These results support that miRNA-150 can be used as a parameter in the monitoring of treatment of CML patients and can contribute to the early detection of drug resistance.
format Article
id doaj-art-91ef4d4bd40c470fb895ef9dc9dd1754
institution OA Journals
issn 2619-9203
language English
publishDate 2025-04-01
publisher Kirsehir Ahi Evran University
record_format Article
series Ahi Evran Medical Journal
spelling doaj-art-91ef4d4bd40c470fb895ef9dc9dd17542025-08-20T02:13:55ZengKirsehir Ahi Evran UniversityAhi Evran Medical Journal2619-92032025-04-0191748110.46332/aemj.1327364Investigation of miR-21, miR-150, miR-155 Expression Levels in Chronic Myeloid Leukemia PatientsHüseyin Avcılar0https://orcid.org/0000-0002-3871-9673Hatice Altın1https://orcid.org/0009-0001-7603-6670Sevil Şimşek2https://orcid.org/0000-0001-5998-6917Leylagül Kaynar3https://orcid.org/0000-0002-2035-9462Erciyes Üniversitesi Tıp Fakültesi İmmünoloji ABDErciyes Üniversitesi Sağlık Bilimleri EnstitüsüErciyes Üniversitesi Sağlık Bilimleri EnstitüsüİSTANBUL MEDİPOL ÜNİVERSİTESİ, TIP FAKÜLTESİPurpose: In this study, the relationship between CML and the expression levels of miR-21, miR-150, and miR-155, which could be used in the follow-up of CML patients, was investigated. Materials and Methods: RNA and miRNA were extracted from peripheral blood samples of patient and control samples. Targe-ted miRNA expression levels from cDNA samples were analyzed by real-time PCR method. Results: miRNA expression level was determined as 1.0 in the control group. In the newly diagnosed group, the mean miR-21 fold change was 0.6, miR-150 fold change was 0.3, and miR-155 fold change was 0.5. fold changes for miR-21, miR-150 and miR-155 were found to be 1.4, 0.5 and 2.4 fold, respectively, in the imatinib treatment group. In the nilotinib treatment group, miR-21 level was 3.5, miR-150 level 0.5, and miR-155 level 4.3. In the dasatinib treatment group, fold change was 0.8 for miR-21, 2.1 for miR-150, and 0.5 for miR-155. The mean miR-21 level was found to be 3.2, miR-150 level 1.0 and miR-155 level 2.8. MiR-150 levels were found to be lower in the newly diagnosed group, imatinib group and nilotinib group than in the control samples. This difference between the new diagnosis group (p=0.07484) and the nilotinib group (p=0.01541) is statistically signi-ficant. No significant difference was found between patients and controls in terms of miR-21 and miR-155 levels. Conclusion: These results support that miRNA-150 can be used as a parameter in the monitoring of treatment of CML patients and can contribute to the early detection of drug resistance.https://dergipark.org.tr/tr/download/article-file/3263928chronic myeloid leukemiamicrornamicrorna-21microrna-150microrna-155
spellingShingle Hüseyin Avcılar
Hatice Altın
Sevil Şimşek
Leylagül Kaynar
Investigation of miR-21, miR-150, miR-155 Expression Levels in Chronic Myeloid Leukemia Patients
Ahi Evran Medical Journal
chronic myeloid leukemia
microrna
microrna-21
microrna-150
microrna-155
title Investigation of miR-21, miR-150, miR-155 Expression Levels in Chronic Myeloid Leukemia Patients
title_full Investigation of miR-21, miR-150, miR-155 Expression Levels in Chronic Myeloid Leukemia Patients
title_fullStr Investigation of miR-21, miR-150, miR-155 Expression Levels in Chronic Myeloid Leukemia Patients
title_full_unstemmed Investigation of miR-21, miR-150, miR-155 Expression Levels in Chronic Myeloid Leukemia Patients
title_short Investigation of miR-21, miR-150, miR-155 Expression Levels in Chronic Myeloid Leukemia Patients
title_sort investigation of mir 21 mir 150 mir 155 expression levels in chronic myeloid leukemia patients
topic chronic myeloid leukemia
microrna
microrna-21
microrna-150
microrna-155
url https://dergipark.org.tr/tr/download/article-file/3263928
work_keys_str_mv AT huseyinavcılar investigationofmir21mir150mir155expressionlevelsinchronicmyeloidleukemiapatients
AT haticealtın investigationofmir21mir150mir155expressionlevelsinchronicmyeloidleukemiapatients
AT sevilsimsek investigationofmir21mir150mir155expressionlevelsinchronicmyeloidleukemiapatients
AT leylagulkaynar investigationofmir21mir150mir155expressionlevelsinchronicmyeloidleukemiapatients